Roche reveals new safety data for haemophilia treatment Hemlibra
No new safety signals identified with longer-term Hemlibra treatment in adult and adolescent patients
Read Moreby Lucy Parsons | Jul 20, 2021 | News | 0
No new safety signals identified with longer-term Hemlibra treatment in adult and adolescent patients
Read Moreby Lucy Parsons | Jun 29, 2021 | News | 0
Company initially withdrew a marketing authorisation application for the gene therapy last year
Read Moreby Selina McKee | Sep 10, 2020 | News | 0
The EMA has asked for full data from an ongoing Phase III study of the treatment in patients with severe haemophilia A
Read Moreby Lucy Parsons | Aug 14, 2020 | News | 0
Clinical trial programme resumes after safety concerns
Read Moreby Selina McKee | Mar 14, 2019 | News | 0
The European Commission has approved Roche and Chugai Pharma UK’s Hemlibra for the prevention of bleeding episodes in people with severe haemophilia A without factor VIII inhibitors, expanding the drug’s treatment scope.
Read Moreby Selina McKee | Nov 28, 2018 | News | 0
Bayer has received EU approval for its hemophilia A treatment, Jivi.
Read Moreby Selina McKee | Oct 5, 2018 | News | 0
Roche’s Hemlibra has been approved in the US for routine prophylaxis of bleeding episodes patients with haemophilia A without factor VIII inhibitors.
Read Moreby Selina McKee | Aug 31, 2018 | News | 0
US regulators have approved Bayer’s Jivi (formerly BAY94-9027), a longer-acting Factor VIII therapy designed to reduce the number of infusions necessary to prevent bleeds in patients with Haemophilia A.
Read Moreby Selina McKee | Feb 28, 2018 | News | 0
Novo Nordisk has filed regulatory applications in the US and European Union seeking approval to market N8-GP for the treatment of haemophilia
Read Moreby Selina McKee | Jan 5, 2018 | News | 0
Roche’s emicizumab in being included in the UK’s Early Access to Medicines Scheme for routine prophylaxis of bleeding episodes in patients with haemophilia A with factor VIII inhibitors.
Read Moreby Selina McKee | Nov 20, 2017 | News | 0
Roche’s Hemlibra has hit key targets in a Phase III trial assessing its effectiveness in preventing bleeds in adults and adolescents with haemophilia A without inhibitors to factor VIII.
Read Moreby Selina McKee | Nov 17, 2017 | News | 0
US regulators have issued a green light for Roche’s haemophilia A therapy Hemlibra and also expanded the scope of Gazyva to include untreated advanced follicular lymphoma.
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479